Covid-19’da Akciğer Tutulumu Şiddeti İle Yağlı Karaciğer Hastalığı Arasındaki İlişkilerin Değerlendirilmesi

Öz

Amaç: Çalışmanın amacı, COVID-19’da pnömoni şiddeti ile yağlı karaciğer hastalığı arasında korelasyon olup olmadığını araştırmaktır.
Materyal ve Metot: Bu çalışmada nazofarengeal sürüntü örneklerine göre COVID-19 pozitif olduğu doğrulanan 168 hastanın göğüs bilgisayarlı tomografi (BT) görüntüleri değerlendirildi. BT görüntülerinde pnömoninin şiddeti ve hepatik steatoz varlığı değerlendirildi.
Bulgular: Hastaların yaşları 26 ile 89 arasında olup, yaş ortalaması 63.6 ± 12.4 yıl idi. Hastaların 101’i (%60.1) erkekti. 51 (%30.4) hastada hepatik steatoz gözlendi. BT’de pnömoni şiddeti ile hepatik steatoz arasında anlamlı fark saptanmadı (p = 0.715). COVID-19 nedeniyle ölen hastalarda hepatik steatoz varlığında iyileşen hastalara göre anlamlı fark saptanmadı (p = 0.938).
Sonuç: Bu çalışma, COVID-19 pnömonisinin şiddeti ile hepatik steatoz arasında bir ilişki olmadığını ortaya koymuştur.

Evaluation of the Correlation Between the Severeness of Lung Involvement and Fatty Liver Disease in Covid-19

Abstract

Aim: The aim of the study is to investigate whether there is a correlation between the severity of pneumonia and fatty liver disease in COVID-19.
Material and Method: In this study chest computed tomography (CT) images of 168 patients who were confirmed to be COVID-19 positive according to nasopharyngeal swab specimens were evaluated. The severity of pneumonia and the presence of hepatic steatosis were evaluated on CT images.
Results: The patients were aged between 26 and 89, and the mean age was 63.6 ± 12.4 years. 101 (60.1%) of the patients were male. Hepatic steatosis was observed in 51 (30.4%) patients. No significant difference between the severity of pneumonia and hepatic steatosis on CT (p = 0.715) was found. No significant difference was found in the presence of hepatic steatosis in patients who died because of COVID-19 compared to patients who recovered (p = 0.938).
Conclusion:This study revealed that there is no relationship between the severity of COVID-19 pneumonia and hepatic steatosis. 

Keywords

• covid-19
• liver
• lung
• ct
• steatosis

Kaynakça

1. 1. Bao C, Liu X, Zhang H, Li Y, Liu J. Coronavirus disease 2019 (COVID-19) CT Findings: A systematic review and meta-analysis. J Am Coll Radiol 2020; 17: 701-9
2. 2. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) [Available from: https: // coronavirus. jhu. edu / map. Htm
3. 3. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382 (18): 1708-20.
4. 4. T.C. Sağlık Bakanlığı, Covid-19 (SARS-CoV-2 Enfeksiyonu) Rehberi Bilim Kurulu Çalışması Ankara; 2020 [updated 14 Nisan 2020; cited 2020]. Available from: https: // covid19 info. saglik.gov.tr/depo/rehberler/COVID-19_Rehberi.pdf.
5. 5. Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y, et al. Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J Hepatol 2020; 73: 451-3.
6. 6. Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, et al. Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR. Radiology 2020; 296: 115-7
7. 7. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395 (10223): 507-13
8. 8. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res 2020; 24: 91-8

9. 9. Mendez IL, Matus JA, Gall SMB et all. Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19).Annals of Hepatology 20 (2021) 100271.
10. 10. Augusto Kreling Medeiros, Cinthia Callegari Barbisan, Italo Ribeiro Cruz et all. Higher frequency of hepatic steatosis at CT among COVID-19-positive patients. Abdominal Radiology volume 45, pages2748-2754 (2020).
11. 11. Omrani-Nava V, Maleki I, Ahmadi A et all. Evaluation of Hepatic Enzymes Changes and Association with Prognosis in COVID-19 Patients. Hepat Mon. 2020 April; 20 (4): e103179.
12. 12. Schmita G, Lelotteb J, Vanhaebost J et all. The Liver in COVID-19-Related Death: Protagonist or Innocent Bystander? Pathobiology 2021; 88: 88-94.
13. 13. Zádori N, Váncsa S, Farkas N, Hegyi P, Eross B, Szakó L, et al. The negative impact of comorbidities on the disease course of COVID-19. Intensive Care Med. (2020) 46: 1784--6. doi: 10.1007 / s00134-020-06161-9
14. 14. Ridruejo E, Soza A. The liver in times of COVID-19: What hepatologists should know. Annals of Hepatology Volume 19, Issue 4, July – August 2020, Pages 353-358.
15. 15. Forlano R, Mullish BH, Mukherjee SK, Nathwani R, Harlow C, Crook P, et al. (2020) Inhospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID19. PLoS ONE 15 (10): e0240400. https://doi.org/ 10.1371 / journal. pone.0240400.
16. 16. Hamer OW, Aguirre DA, Casola G, Lavine JE, Woenckhaus M, Sirlin CB. Fatty liver: imaging patterns and pitfalls. Radiographics 2006; 26: 1637-53.